Skip to main content
Premium Trial:

Request an Annual Quote

Royalties Drive up GeneNews' Q2 Revenues

NEW YORK (GenomeWeb News) – Canadian molecular diagnostics company GeneNews said after the close of the market Thursday that revenues for the second quarter increased nearly six-fold year over year.

The company posted C$56,304 (US$56,569) in revenues for the three months ended June 30, up from C$9,790 a year ago. GeneNews recorded C$51,833 in royalty payments, compared to zero a year ago, while sales were down to C$4,471 from C$9,790.

In April, the firm launched ColonSentry, a blood-based colon cancer risk stratification test, in the US through its marketing partner Enzo Clinical Labs. GeneNews President and CEO Gailina Liew said in a statement that Enzo "reports that early interest shown by doctors and patients in their initial launch into New York and New Jersey has been high and current efforts are focused on increasing lab capacity and an expanded launch."

The firm's R&D spending in the quarter rose 2 percent to C$438,660 from C$430,605 a year ago, and SG&A costs were up 49 percent to C$728,164 from C$487,899.

GeneNews had a net loss of C$1.3 million, or C$.01 per share, compared to a net loss of C$1.1 million, or C$.01 per share, a year ago.

Cash and cash equivalents at the end of the quarter totaled C$431,074, the company said.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.